Early histopathological changes in new-onset diabetes after kidney transplantation

Transplant Proc. 2014 Jul-Aug;46(6):2155-9. doi: 10.1016/j.transproceed.2014.05.057.

Abstract

Background: New-onset diabetes after transplantation (NODAT) is one of the most common complications after kidney transplantation.

Methods: Patients were randomly assigned to receive cyclosporine A-based or tacrolimus-based immunosuppression. Fasting and oral glucose tolerance tests were performed, and the patients were assigned to one of the following 3 groups, on the basis of the results: normal, impaired fasting glucose/impaired glucose tolerance, or NODAT. NODAT developed in 14% of patients receiving cyclosporine A-based immunosuppression and in 26% of patients taking tacrolimus (P = .0002).

Results: Albumin levels were similar, but uric acid level (P = .002) and the age of the recipient (P = .003) were significantly different between the diabetic and the normal groups. Evaluation of tissue samples revealed that acute cellular rejection and interstitial fibrosis/tubular atrophy were significantly different in the NODAT group. Changes in the Banff score provided significant difference regarding tubulitis and interstitial inflammation (P = .05).

Conclusions: The pathological effect of new-onset diabetes after kidney transplantation can be detected in the morphology of the renal allograft earlier, before the development of any sign of functional impairment.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Biopsy
  • Diabetes Mellitus / etiology
  • Diabetes Mellitus / pathology*
  • Early Diagnosis*
  • Female
  • Graft Rejection / complications*
  • Graft Rejection / drug therapy
  • Graft Rejection / pathology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Risk Factors
  • Tacrolimus / therapeutic use
  • Transplantation, Homologous / adverse effects

Substances

  • Immunosuppressive Agents
  • Tacrolimus